The grades of 11 Pharmaceuticals stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This week, GW Pharmaceuticals PLC Sponsored ADR (GWPH) pushes up from a C to a B rating. The company also gets A’s in earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of GWPH stock.
ANI Pharmaceuticals, Inc.’s (ANIP) ratings are looking better this week, moving up to a B from last week’s C. ANI Pharmaceuticals, Inc. develops, manufactures, and markets prescription and over-the-counter pharmaceuticals. The company also gets A’s in sales growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of ANIP stock.
Merck & Co., Inc. (MRK) boosts its rating from a B to a A this week. Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company also gets A’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of MRK stock.
This week, GlaxoSmithKline plc Sponsored ADR’s (GSK) ratings are up from a C last week to a B. GlaxoSmithKline plc Sponsored ADR is a research-based pharmaceutical company. The company also gets A’s in return on equity. For more information, get Portfolio Grader’s complete analysis of GSK stock.
Aerie Pharmaceuticals, Inc. (AERI) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of AERI stock.
This is a strong week for Dermira Inc (DERM). The company’s rating climbs to B from the previous week’s C. For more information, get Portfolio Grader’s complete analysis of DERM stock.
The rating of Supernus Pharmaceuticals, Inc. (SUPN) moves up this week, rising from a B to a A. Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets proprietary drugs for the treatment of central nervous system diseases and disorders. The company also gets A’s in sales growth, earnings growth, earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of SUPN stock.
Depomed, Inc. (DEPO) earns a B this week, jumping up from last week’s grade of C. Depomed, Inc. develops new and proprietary oral drug delivery technologies. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of DEPO stock.
Amphastar Pharmaceuticals, Inc. (AMPH) is seeing ratings go up from a B last week to a A this week. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of AMPH stock.
Innoviva, Inc. (INVA) improves from a C to a B rating this week. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of INVA stock.
Corcept Therapeutics Incorporated. (CORT) gets a higher grade this week, advancing from a C last week to a B. Corcept Therapeutics Incorporated. engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of CORT stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
